Brawn Biotech Ltd
₹ 20.4
4.98%
24 Apr
- close price
- Market Cap ₹ 6.13 Cr.
- Current Price ₹ 20.4
- High / Low ₹ 26.8 / 14.4
- Stock P/E
- Book Value ₹ 19.0
- Dividend Yield 0.00 %
- ROCE -5.91 %
- ROE -12.9 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 1.07 times its book value
- Company's working capital requirements have reduced from 133 days to 80.6 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -16.8% over past five years.
- Company has a low return on equity of -12.9% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
15.01 | 25.70 | 34.42 | 38.65 | 46.88 | 59.78 | 55.71 | 65.18 | 49.62 | 34.98 | 8.53 | 22.23 | 13.17 | |
14.75 | 25.07 | 33.97 | 38.09 | 45.44 | 58.53 | 53.75 | 64.01 | 48.89 | 35.58 | 10.53 | 22.53 | 14.26 | |
Operating Profit | 0.26 | 0.63 | 0.45 | 0.56 | 1.44 | 1.25 | 1.96 | 1.17 | 0.73 | -0.60 | -2.00 | -0.30 | -1.09 |
OPM % | 1.73% | 2.45% | 1.31% | 1.45% | 3.07% | 2.09% | 3.52% | 1.80% | 1.47% | -1.72% | -23.45% | -1.35% | -8.28% |
0.00 | 0.04 | -0.07 | 0.04 | 0.01 | 0.61 | 0.09 | 0.74 | 0.17 | 0.31 | 0.00 | 0.01 | 0.23 | |
Interest | 0.05 | 0.08 | 0.14 | 0.10 | 0.11 | 0.07 | 0.06 | 0.07 | 0.05 | 0.04 | 0.06 | 0.01 | 0.00 |
Depreciation | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.11 | 0.08 |
Profit before tax | 0.20 | 0.58 | 0.23 | 0.47 | 1.31 | 1.76 | 1.96 | 1.81 | 0.82 | -0.36 | -2.11 | -0.41 | -0.94 |
Tax % | 90.00% | 37.93% | 39.13% | 40.43% | 27.48% | 20.45% | 34.69% | 26.52% | 28.05% | -55.56% | 22.27% | -109.76% | |
0.02 | 0.35 | 0.14 | 0.28 | 0.95 | 1.39 | 1.28 | 1.33 | 0.59 | -0.55 | -1.64 | -0.87 | -0.97 | |
EPS in Rs | 0.07 | 1.17 | 0.47 | 0.93 | 3.17 | 4.63 | 4.27 | 4.43 | 1.97 | -1.83 | -5.47 | -2.90 | -3.23 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 31.58% | 32.37% | 23.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -1% |
5 Years: | -17% |
3 Years: | -23% |
TTM: | -23% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -473% |
Stock Price CAGR | |
---|---|
10 Years: | 14% |
5 Years: | -12% |
3 Years: | -8% |
1 Year: | 20% |
Return on Equity | |
---|---|
10 Years: | 5% |
5 Years: | -3% |
3 Years: | -13% |
Last Year: | -13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
Reserves | 1.18 | 1.53 | 1.68 | 1.94 | 2.53 | 3.92 | 4.63 | 5.66 | 6.26 | 5.79 | 4.22 | 3.31 | 2.71 |
0.02 | 0.02 | 0.01 | 0.11 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
8.27 | 9.02 | 9.00 | 8.95 | 8.30 | 10.11 | 14.94 | 13.85 | 11.03 | 5.08 | 6.56 | 8.22 | 6.02 | |
Total Liabilities | 12.47 | 13.57 | 13.69 | 14.00 | 13.95 | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 11.73 |
0.08 | 0.08 | 0.07 | 0.19 | 0.24 | 0.25 | 0.22 | 0.19 | 0.18 | 0.14 | 0.39 | 0.37 | 0.35 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
12.36 | 13.46 | 13.59 | 13.78 | 13.68 | 16.78 | 22.35 | 22.32 | 20.11 | 13.73 | 13.39 | 14.16 | 11.38 | |
Total Assets | 12.47 | 13.57 | 13.69 | 14.00 | 13.95 | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 11.73 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.05 | 0.18 | 0.23 | 0.05 | 1.37 | -1.54 | 0.21 | -0.08 | 0.03 | 0.19 | 0.32 | ||
0.00 | -0.01 | -0.12 | -0.08 | 0.57 | 0.00 | 0.00 | -0.02 | 0.00 | -0.30 | -0.10 | ||
-0.08 | -0.15 | 0.00 | -0.05 | -0.11 | -0.06 | -0.06 | -0.05 | -0.04 | -0.06 | -0.01 | ||
Net Cash Flow | -0.03 | 0.02 | 0.11 | -0.08 | 1.83 | -1.60 | 0.15 | -0.14 | 0.00 | -0.17 | 0.21 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 133.74 | 112.62 | 88.65 | 87.07 | 71.63 | 79.50 | 98.60 | 92.17 | 110.34 | 96.83 | 120.24 | 87.35 |
Inventory Days | 149.79 | 35.63 | 22.14 | 11.17 | 4.50 | 2.59 | 2.62 | 2.12 | 3.38 | 3.16 | 261.82 | 91.20 |
Days Payable | 278.48 | 147.43 | 87.79 | 73.72 | 44.59 | 47.70 | 83.93 | 64.58 | 74.47 | 32.34 | 224.66 | 123.19 |
Cash Conversion Cycle | 5.05 | 0.83 | 23.01 | 24.52 | 31.54 | 34.39 | 17.29 | 29.72 | 39.25 | 67.65 | 157.41 | 55.36 |
Working Capital Days | 8.75 | 11.22 | 15.59 | 15.87 | 18.92 | 28.21 | 43.37 | 42.06 | 58.04 | 77.53 | 241.76 | 80.62 |
ROCE % | 5.98% | 15.09% | 24.89% | 11.91% | 26.54% | 29.28% | 27.77% | 23.08% | 9.71% | -3.55% | -25.61% | -5.91% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
12 Apr - Filing Annual Secretarial Report is not applicable on the company as per Regulation 15(2) of SEBI(LODR) Regulations,2015.
-
Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015.
11 Apr - Compliance certificate under Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the period 1 April 2023 to 31 March 2024.
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 10 Apr
- Compliance Certificate Under Regulation 40(9) Of LODR For The Financial Year Ended On 31St March 2024 9 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
Business Overview:[1][2]
Company is a fully integrated healthcare company having product registration with health and govt. institutions in India and abroad. It deals in Critical Care range of Products along with other Pharmaceutical products. Company's Pharmaceutical Formulations cover all major product segments viz. Anti-bacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti asthmatics, Antacids, Anti-malarial, and Nutritionals